<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127096</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00100</org_study_id>
    <nct_id>NCT05127096</nct_id>
  </id_info>
  <brief_title>Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas</brief_title>
  <official_title>Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CellMax Life</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CellMax Life</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect clinical specimens from subjects with a diagnosis of&#xD;
      colorectal cancer/advanced adenoma or undergoing a screening colonoscopy and meeting study&#xD;
      eligibility criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity for CRC of the FirstSight test</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of the FirstSight test</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Colorectal Cancer Screening</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>Cohort A will include subjects with a recent diagnosis of colorectal cancer and/or advanced adenoma requiring additional endoscopic or surgical resection (surgery).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <description>Cohort B will include subjects undergoing routine screening colonoscopies will be enrolled in the screening cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FirstSight blood test</intervention_name>
    <description>FirstSight blood test for colorectal cancer screening</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort A: This cohort will include subjects with a recent diagnosis of colorectal cancer or&#xD;
        advanced adenoma requiring surgical resection.&#xD;
&#xD;
        Cohort B: This cohort will include subjects undergoing routine screening colonoscopies for&#xD;
        colorectal cancer as part of their regular medical assessment regimen.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To enroll in Cohort A, a subject must:&#xD;
&#xD;
          -  Be 45-80 years of age (inclusive) at the time of screening.&#xD;
&#xD;
          -  Be recently diagnosed with primary colorectal cancer or advanced adenoma with plans to&#xD;
             surgically remove the target lesion.&#xD;
&#xD;
        To enroll in Cohort B, a subject must:&#xD;
&#xD;
          -  Be 45-80 years of age (inclusive) at the time of screening.&#xD;
&#xD;
          -  Be planning to undergo a screening colonoscopy within 30 days after providing signed&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        To enroll in Cohort A, a subject must NOT have:&#xD;
&#xD;
          -  Inflammatory bowel disease (IBD)&#xD;
&#xD;
          -  Personal or family history of colorectal cancer syndromes or other hereditary cancer&#xD;
             syndromes&#xD;
&#xD;
        To enroll in Cohort B, a subject must NOT have:&#xD;
&#xD;
          -  Personal history of colorectal cancer, colorectal adenoma or aerodigestive tract&#xD;
             cancer.&#xD;
&#xD;
          -  Personal or family history of Familial adenomatous polyposis (FAP).&#xD;
&#xD;
          -  Personal or family history of Hereditary non-polyposis colorectal cancer syndrome&#xD;
             (HNPCC or Lynch Syndrome).&#xD;
&#xD;
          -  Positive fecal occult blood testing (FOBT) within the previous 6 months.&#xD;
&#xD;
          -  Positive fecal immunochemical testing (FIT) in the previous 6 months.&#xD;
&#xD;
          -  Colorectal resection for any reason other than sigmoid diverticular disease.&#xD;
&#xD;
          -  Overt rectal bleeding within the previous 30 days.&#xD;
&#xD;
          -  Personal history of any cancer diagnosed &lt;5 years prior.&#xD;
&#xD;
          -  Inflammatory bowel disease (IBD), including chronic ulcerative colitis (CUC) and&#xD;
             Crohn's disease.&#xD;
&#xD;
          -  Colonoscopy within the previous 9 years.&#xD;
&#xD;
          -  Barium enema, computed tomographic colonography, or sigmoidoscopy within the previous&#xD;
             5 years.&#xD;
&#xD;
          -  â‰¥ 2 first-degree relatives who have been diagnosed with colorectal cancer (Note: First&#xD;
             degree relatives include parents, siblings and offspring).&#xD;
&#xD;
          -  1 first-degree relative with CRC diagnosed before the age of 60.&#xD;
&#xD;
          -  Have participated or be currently participating in a clinical research study in which&#xD;
             an experimental medication has been administered during the 30 days up to and&#xD;
             including the date of providing informed consent or may be administered through the&#xD;
             time of the colonoscopy.&#xD;
&#xD;
          -  Have a medical condition which, in the opinion of the investigator, should preclude&#xD;
             enrollment into the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rui Mei, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CellMax Life</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ben Hsieh, PhD</last_name>
    <phone>650-814-8088</phone>
    <email>ben@cellmaxlife.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen Su, PhD</last_name>
    <phone>408-887-7640</phone>
    <email>stephensu@cellmaxlife.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CellMax Site A</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CellMax Site O</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CellMax Site L</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CellMax Site J</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CellMax Site P</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CellMax Site D</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CellMax Site G</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CellMax Site C</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CellMax Site B</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CellMax Site N</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CellMax Site M</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CellMax Site K</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CellMax Site E</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CellMax Site F</name>
      <address>
        <city>Pasadena</city>
        <state>Texas</state>
        <zip>77504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CellMax Site H</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

